Overview

Globally, cardiovascular disease (CVD) is the leading cause of death, with a resurgence in higher-income countries and higher prevalence in low- and middle-income countries. While there have been many advancements made to this indication using wearables and advanced diagnostics and devices, growth in therapeutics has been veiled.

Traditional pharmacotherapy faces the drawback of being highly invasive and causing damage to the liver, kidneys, and other organs, as well as having other side effects. In addition, cardiac surgeries are complex procedures with the possibility of postoperative complications.

• How can your team leverage advancements in wearables and diagnostics to drive growth in cardiovascular therapeutics?
• How can advancements in gene therapies, gene editing platforms, RNA therapies, and regenerative medicine drive transformation and accelerate growth in the treatment of CVDs?
• How can the adoption of new enabling technologies enhance the drug development pipeline for CVDs paving the way for growth in this landscape?

Quick links

Click here to download the sample of this analysis

Already a member? Click here to access the analysis

Frost Honorarium Program

Unlock a $1,000 Incentive with a Complimentary Growth Dialog

Engage with our industry experts for a discussion to explore new growth opportunities for your business.

As a token of appreciation, you will receive a $1,000 honorarium—redeemable towards any of our products or services.

Schedule Your Growth Dialog Today!